Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Fimasartan
Yung NA
Essential Hypertension
1 trial -
Fimasartan/Atorvastatin Combination Tablet
Yung NA
Hypertension
1 trial -
GK01 Injection
The First People's Hospital of Lianyungang
Advanced Solid Tumors
1 trial -
GMCN-508B (LentiRed)
The First People's Hospital of Lianyungang
Transfusion Dependent Beta-Thalassemia
1 trial -
GPC3 and/or TGFΞ² targeting CAR-T cells
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
GPRC5D CAR-T cell intravenous infusion
The First People's Hospital of Lianyungang
Plasma Cell Dyscrasias
1 trial -
GST-HG121 tablets
The First People's Hospital of Lianyungang
Pharmacokinetics
1 trial -
Gallium-68 NODAGA-JR11
The First People's Hospital of Lianyungang
Neuroendocrine Tumors
1 trial -
HER2 Tumor Vaccine
The First People's Hospital of Lianyungang
Adenocarcinoma - GEJ
1 trial -
HSK3486
The First People's Hospital of Lianyungang
Chronic Renal Impairment
1 trial -
HSK3486
The First People's Hospital of Lianyungang
Healthy Elderly Subjects
1 trial -
HY-2003 (10 mg/ml), BELKYRA and placebo
The First People's Hospital of Lianyungang
Moderate or Severe Submental Fullness
1 trial -
Hema-NeoTIL01
The First People's Hospital of Lianyungang
Leukemia, Myeloid, Acute
1 trial -
Human BCMA targeted T Cells Injection
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Human Umbilical Mesenchymal Stem Cells
The First People's Hospital of Lianyungang
Osteoarthritis, Knee
1 trial -
Human amniotic-derived mesenchymal stem cells
The First People's Hospital of Lianyungang
Chronic Kidney Diseases
1 trial -
Hydronidone capsules
The First People's Hospital of Lianyungang
Liver Fibrosis
1 trial -
IBR733 Cell Injection
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
ICI201
The First People's Hospital of Lianyungang
Relapsed/Refractory Multiple Myeloma
1 trial -
JWCAR129
The First People's Hospital of Lianyungang
Safety and Efficacy
1 trial -
JY306 universal NK cell injection
The First People's Hospital of Lianyungang
Relapsed or Refractory Hematological Malignancies
1 trial -
KXV01 TCR Lentinvivo Injection
The First People's Hospital of Lianyungang
Advanced Solid Tumors
1 trial -
KXV01 TCR Lentinvivo Injection
The First People's Hospital of Lianyungang
Advanced Solid Cancer
1 trial -
Keverprazan
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources